Q1 2022 Results

Company overview Financial review 2022 priorities Appendix References Q1 Group core margin increased by 110bps to 32.6% driven by Sandoz which benefitted from low PY base Q1 2022 Net sales change vs PY1 Core operating income change vs. PY1 Core margin¹ % CC % CC % Core margin change vs. PY1 %pts cc Innovative Medicines 4 5 35.9 0.2 Sandoz 8 26 22.8 3.3 Group 5 9 32.6 1.1 1. Constant currencies (cc), core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 35 of the Condensed Interim Financial Report. 23 Investor Relations | Q1 2022 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation